Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Restricted accessLetterFirst published online April, 2022
Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
BissellBDMeffordBDonaldsonJC. Comment: Low-dose tocilizumab with high-dose corticosteroids in patients hospitalized for COVID-19 hypoxic respiratory failure improves mortality without increased infection risk. Ann Pharmacother. doi:10.1177/10600280211036040
2.
BrosnahanSBChenXJCChungJ, et al. Low-dose tocilizumab with high-dose corticosteroids in patients hospitalized for COVID-19 hypoxic respiratory failure improves mortality without increased infection risk. Ann Pharmacother. Published online June 28, 2021. doi:10.1177/10600280211028882
3.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT Working Group; Shankar-HariMValeCL, et al). Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. Published online July 6, 2021. doi:10.1001/jama.2021.11330
4.
AngusDCDerdeLAl-BeidhF, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317-1329. doi:10.1001/jama.2020.17022
5.
MeduriGUGoldenEFreireAX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131:954-963. doi:10.1378/chest.06-2100
6.
TongyooSPermpikulCMongkolpunW, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20:329. doi:10.1186/s13054-016-1511-2
7.
VillarJFerrandoCMartínezD, et al; Dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267-276. doi:10.1016/s2213-2600(19)30417-5
8.
FatimaSAAsifMKhanKASiddiqueNKhanAZ.Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. Ann Med Surg (Lond). 2020;60:413-416. doi:10.1016/j.amsu.2020.11.027
9.
PinzónMAOrtizSHolguínH, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16:e0252057. doi:10.1371/journal.pone.0252057
10.
RanjbarKMoghadamiMMirahmadizadehA, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21:337. doi:10.1186/s12879-021-06045-3
11.
KoJJWuCMehtaNWald-DicklerNYangWQiaoR.A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. J Intensive Care Med. 2021;36:673-680. doi:10.1177/0885066621994057
12.
RosasIOBräuNWatersM, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503-1516. doi:10.1056/NEJMoa2028700
13.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645. doi:10.1016/s0140-6736(21)00676-0
